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Abstract
Medication safety should be at the forefront of public health initiatives.
Medication reconciliations in primary care are key to successful, accurate, and safe
medication use. Pharmacists are well positioned and educated to have an impact on
medication safety by conducting reconciliations in primary care centers. Guidelines
for training pharmacists on how to conduct medication reconciliations would be a
useful tool for any health board striving to improve medication safety. This study
uses observations from pharmacists currently conducting medication reconciliations
in primary care to propose such guidelines in the form of a flow sheet. The resulting
flow sheet and observations are provided.
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Introduction
The Scottish Government defines medicine reconciliation as: ‘The process the
healthcare team undertakes to ensure the list of medication, both prescribed and over
the counter, that I am taking is exactly the same as the list I or my carers, general
practitioner, community pharmacist and hospital team have. This is achieved in
partnership with me through obtaining an up-to-date and accurate medication list that
has been compared with the most recently available information and has documented
any discrepancies, changes, deletions or additions resulting in a complete list of
medicines accurately communicated.’(1) Medication reconciliation as defined by
Bandrés et al. is “the process of reviewing patients complete previous medication
regimen, comparing it with current prescriptions, and analyzing or resolving any
discrepancies that the pharmacist does not believe to be intentional.”( 2)
There is evidence of greater risk of error and potential harm from medicines at
the interface between care settings. (1) Some sources have indicated that more than half
of all medication errors occur at these transitions. (2) The Scottish Patient Safety
Programme (SPSP) is a national initiative which aims to reduce harm. A core work
stream of the program is to achieve safe systems for reconciling medicines in General
Practitioner (GP) practices following hospital discharge. (3) A care bundle for the
medicine reconciliation (MR) process has been developed by the SPSP. (4) NHS
Greater Glasgow and Clyde tested the care bundle on a small scale and followed with
large scale implementation. Of the 200 GP practices responding, 85% reported the
MR work had improved patient safety and 80% reported that it had led to improved
practice processes. (4) Although the process required additional time, this was offset by
time saved correcting medication issues at a later stage. Quality improvement
methodology was used in a UK hospital with the aim of reducing discrepancies in
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transcribing medication at admission to hospital and improving documentation and
communication of MR on hospital discharge. Immediate discharge letters and clinic
letters serve as the avenue of communication between the patient’s primary care
provider and the hospital or specialty clinic responsible for discharge. This
communication is crucial to the proper management of the patient’s medications and
highlights a strikingly obvious potential failure in continuity of care. Post study audit
of discharge summaries showed reliable documentation improved from 49.2% to
85.2%.(5) Local SPSP audit data reported a reduction in error rate on hospital
immediate discharge letters (IDLs) of 87% and an increase in accuracy following a
change in the structure of the IDL template and addition of a second senior doctor
signature.(6) This supports the use of IDLs for effective transitions; if the process of
using the information provided can be effectively implemented in primary care.
Evaluation of the medication reconciliation process in primary care to identify
and categorize the care issues arising from inpatient and outpatient immediate
discharge letters is important for ensuring cost-effective and safe transitions of care in
Scotland. Increasingly, pharmacists are contributing to the medication reconciliation
process in GP practices around Scotland. However, it has been shown that
identification of errors or discrepancies does not always lead to an improvement in
workload. (7) Thus, the NIH in Scotland has resolved to ensure proper implementation
of a medication reconciliation system. The efficiency of this system could be
enhanced following a review of the process of writing, sending, receiving, and acting
upon clinic letters and IDLs as part of the medication reconciliation process. A
medicine reconciliation guideline in primary care in the form of a flowchart
incorporating the SPSP care bundle could lead to improved transitions, workload, and
patient outcomes. This flow diagram was developed as a guideline for all primary care
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pharmacists carrying out MR in GP practices. Through careful evaluation of the
logistics and actions needed to provide accurate medication reconciliation for patients,
a standardized process will be recommended for all GP practices. Standardization of
this process increases the level of patient care by reducing medication errors,
increasing the validity of the patient’s medication list found in GP records upon
discharge from outpatient clinics and inpatient stays, and improving workflow in
primary care clinics across the NIH.
The issues and processes discussed above are of immense public health
importance for many reasons. First, the primary care sector of healthcare is well
known for deficiencies in access. Additionally, it is well known that transitions of
care between different healthcare environments such as from hospitals and medical
centers to the general practitioners’ offices lead to medication errors and in return
unnecessary healthcare dollar expenditures relayed to errors. Pharmacist’s facilitated
cost savings has been demonstrated through medication reconciliations, collaborative
drug therapy management, and therapeutic alternative substitutions.(8) Additionally, it
has been shown that pharmacists in close working relationships with physicians in the
inpatient setting can lead to a decrease length of stay and avoidance of preventable
adverse drug reactions.(9) A study examining medication reconciliation from Spain
found that physicians agreed with pharmacists clinical judgment for evaluating errors
93% of the time.(2) Furthermore, it has been shown that pharmacist led interventions
have been more effective at identifying clinically impactful discrepancies than usual
methods for transitions of care.(10,11) Due to the potential benefit pharmacists can have
on transitions of care, adverse drug events, medication errors, time, and cost savings,
a stream of pharmacists moving towards more clinical roles in the primary care setting
should be a natural public health objective. This is supported by Ensing et al., who
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reported that close collaboration between pharmacists and physicians integrated
across many settings and locations is beneficial for identifying potentially serious
medication errors. (12) Furthermore, proper implementation of pharmacists in these
primary care setting is essential for ensuring public health benefit.
Aim
To undertake an evaluation of the medicine reconciliation process in primary care in a
Scottish health board.
Objectives
1. Design a medication reconciliation procedure specific to the GP Practices
where pharmacist driven reconciliation is undertaken.
2. Design and pilot a data collection tool to record information from observations
of general practitioners and pharmacists undertaking the medication
reconciliation process.
3. Improve the efficiency and accuracy of pharmacist led medication
reconciliation by providing standardized guidelines in the form of a flow chart
for the process of medication reconciliation based on study results.
4. To record care issues identified in the medication reconciliation process,
categorize them, and rate their severity of care issues using recognized tools.
Design
The study design was a prospective observation of pharmacists’ and general
practitioners’ medication reconciliation processes within the primary care setting in a
Scottish Health Board. Potential medication reconciliations were identified in GP
practices as IDLs from hospital inpatient admissions or outpatient clinic letters
received at the practice.

7

Local approval was sought from the Pharmacy Quality Improvement Team of
NHS Lothian. Individual GP and pharmacist permission for observation of the
reconciliation process was requested, those who accepted completed an agreement
form (appendix 1) and a copy of the protocol was provided. All discharges from
clinics and hospitals to the identified GP practices were eligible. All pharmacists were
chosen on a convenience and willingness basis. Patients were excluded if the hospital
stay resulted in death or if the patient was admitted and discharged with no
medications. Letters or discharges that were deemed duplicates were counted, but left
out of any statistical information.
Methods
A template (appendix 2) was designed to incorporate all elements involved in
the MR process in GP practices. A guideline was incorporated and the template
completed for the individual GP practices where pharmacists were currently
preforming MRs to form a procedure specific to primary care pharmacy practice in
the identified GP practices.
A data collection tool was designed and piloted through observation of a
pharmacist undertaking MR in one GP practice. Next, data was collected over a threeweek period in four GP practices through observance by the investigator of four
pharmacists with the aim of collecting approximately 100 patient MR episodes. GP
MR was intended to be observed in practices where there is no pharmacist
contribution to the MR process. The tool was targeted at collecting process data
including: time spent to complete a MR event, date of IDL received and date of
discharge or clinic attendance, number of medicines per MR event, number of MR
events requiring follow up and type of follow up, whether patient has medication
compliance aid. The tool used can be found in appendix 3.
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Process totals and percentages were reported and can be found in appendix 4.
Data from pharmacist MR and GP MR were compared and contrasted. A report was
produced and an oral presentation of results was made to the primary and secondary
care pharmacy team meeting. Results were obtained by weighting each of the four
practices equally in order to avoid skewing of the data based on unequal sample sizes.
The tool recorded the number of care issues identified by pharmacists and GPs
in the MR process for each patient. The investigator subsequently categorized the
issues and rated the severity (minor, significant, serious, and potentially lethal)
according to the EQUIP5 criteria. Significant and potentially lethal issues were
recorded in a situation, background, assessment, recommendation (SBAR) format.
Care issue categorization and severity rating were peer reviewed by the supervisor.
Results
The template for developing the necessary procedures during MR was
proposed in the beginning of the study. This template included all aspects of the
suspected MR process map, this document can be found in appendix 2.
The data collection tool can be found in appendix 3. This tool was developed
using the template and then piloted successfully based on observation of five MRs
tasked to a pharmacist from one GP practice and then updated accordingly for this
study. After three weeks of data collection, 93 total MRs were observed. There were
nine duplicates found in this sample (9.6%) leaving 84 total observations. Of the four
GP practices surveyed, the distribution for contribution to our study was not equal.
This is exemplified in the following chart:

9

Table 1: Overview of Observations
Practice Number

Number of Observations

Practice 1

9

Practice 2

14

Practice 3

21

Practice 4

40

Total

84

There were no results available from observation of GPs as this aspect of the
intended study was not successfully completed. There was a retrospective analysis of
seven MRs completed by GPs in which 0% of the changes made by the GP were
noted in the patient’s chart using the MR read-code.
The next section of results concentrates on quantitative workflow measures.
Starting with the process of letters being received by the GP practices, notably the
largest delay in information was seen between the patient’s visit or discharge and the
day their letter was written by the discharging entity (5.2 ± 4.6 days on average). The
second longest delay was between the day the letter was written and when it was
received by the GP practice (2.6 ± 0.3 days on average). Lastly, the shortest delay was
found between the day the letter was received by the practice and the day it was
processed by a pharmacist (1.3 ± 0.8 days on average). Additionally, pharmacists
completed the medication reconciliations within 48 hours of the letter being received
about 91% of the time on average.
Next, pharmacists’ completion of the MR process was timed. The average
amount of time for processing a discharge letter was 7.0 ± 0.7 minutes, while the
average for a clinic letter was 9.6 ± 3.6 minutes. Interestingly, Practice 1, a sample of
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8 observations, had an average clinic letter completion time of 14.8 minutes and no
discharge letters in the sample, this was not seen in the observations from other
practices.
Qualitative process validation and quality assurance results were gathered
using the tool developed for this study. First, the proportion of medication
reconciliations which found an error in the clinic or discharge letter varied greatly.
Changes were made to the patient’s chart 82.2% of the time between the practices. If
there were no changes to be noted on the chart the observation was not counted
towards our calculation of the proportion of MRs in which pharmacists added the
proper changes to the chart. Importantly, the medication reconciliation read-code was
used on average 92.3% of the time.
Next, it was found that whether or not the pharmacist analyzed the patient’s
repeat list for other changes to be made unrelated to the letter received varied greatly
between practices. This is evident in that Practice 4 attempted to remove outdated
repeats 100% of the time, while Practice 2 analyzed the other repeats on 46.1% of the
medication reconciliations. Similarly, allergies were checked by some practices,
100% of the time by Practice 4, but never by practice 2 at 0%. Lastly, patients and
caregivers were contacted 33.25% of the time on average.
MRs in which errors were found were forwarded to GPs for further assistance
18.3% of the time. Pharmacists exercised their clinical decision making skills on
38.7% of the MRs with in some capacity. Notably, the amount of clinical decision
making varied with 71.4% of the errors at Practice 4 resolved by the pharmacist
compared to 16.7% of those at Practice 1. There are no results from any SBARs
(situation, background, assessment, recommendation) for the issues encountered as

11

the information was not as readily available as anticipated. A more detailed
breakdown of the results can be found in appendix 4.
Discussion
The template for conducting this project was useful for developing both the
data collection tool and final flow diagram. The data collection tool was useful for the
purposes it was designed. However, some of the findings in this study cannot be
explained using statistics. Specifically, it became extremely difficult to understand the
process utilized by GPs to perform medication reconciliations. This is in part due to
the technique the GPs utilize in terms of time management with MRs. The observed
standard for GPs is that MRs fit into random slots of spare time, making planned
observation for study purposes nearly impossible. Upon speaking with GPs it became
clear that they tend to make all necessary medication changes highlighted in the letters
received, without adding any notes in the patient’s chart. Additionally, GPs do not
use the medication reconciliation read-code. The importance of the read-code is that it
enables fellow professionals to search the patient’s chart regarding the information
contained in the letter where the changes originated. Without these events coded into
the patient chart, finding the letter from which the changes were made involves an
inefficient search through the Docman system. The Docman system holds electronic
copies of letters regarding that patient throughout the course of their care, thus it can
be cumbersome to find specific documents. This was somewhat supported by the
retrospective analysis of seven MRs completed by GPs. Illustrating the importance of
this read-code to GPs could be a beneficial exercise.
Scottish patient safety program guidelines note all letters should be processed
within 48 hours of being received. Pharmacists managed to reach this guideline 91%
of the time. The greatest time lag in the process is between the patient visit or
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discharge and the day the letter is actually written. There are no guidelines in place to
ensure efficient writing and delivery of these letters for each patient visit. It is
paradoxical to have guidelines urging GP practices to process a letter within 48 hours
when it’s possible that letter was written two weeks after the patient’s visit or
discharge. This sheds light on future study ambitions in order to streamline the MR
processing between healthcare locations.
The time for pharmacists to complete MRs was found to be very similar across
three of the practices with a range of 6.2-7.5 minutes for discharge letters and 6.7-8.9
for clinic letters. The results gathered do become confounded by Practice 1, which had
an average completion time of 14.8 minutes. Notably, observations of clinic letters
and no IDLs were obtained at this practice. Possible implications of this are that the
overall pharmacists’ time spent on average for clinic letters is skewed by this practice,
while the IDL average is not. This difference could account for the 9.6-minute
average for clinic letters versus the 7.0-minute average for IDLs. Explanations for this
possible anomaly include a small sample size since Practice 1 was the smallest sample
in the study. Another explanation could be that the pharmacist in that practice is not as
experienced with MR. However, it is especially worth noting that the cases could
have been more complicated on average, which may be reflected in the rate of errors
found being more than double that of any other practice. Interestingly, 72.7% of errors
in the study were found in clinic letters. More information on the errors and their
severity are highlighted in appendix 6 and will be discussed below.
Our findings identified pharmacists as important members of the primary care
team through their dedication to updating patients’ charts. It was clear early on that
pharmacist’s consistently use the MR read-code (92.3%). In some cases, pharmacists
would input the read-code and letter information after a GP had already seen the letter

13

and made changes. This illuminates the GPs tendency to make changes, but not input
the letter details so they could be easily tracked.
Pharmacists did seem to diverge in the process upon continued evaluation. The
data showed that some pharmacist always checked and attempted to update allergy
information during the MR process while some never did. The same was found for
pharmacist’s ensuring the patient’s repeat list could not be updated. The repeat list
that has been referred to thus far may be misunderstood by healthcare professionals in
the United States; however, it simply refers to the medications a patient is intended to
get every month, similar to a list of maintenance medications. However, medications
not intended to be part of the patient’s medication list chronically are often added to
the repeat list. This mistake occurs when the patient calls the GP for a given
medication, that they were meant to be taking acutely, to be filled again. Then due to
time constraints a GP may never fully review whether or not that patient should be
taking the medication chronically, unfortunately a “repeat request” may be the only
information seen, so they give them another month’s supply to avoid further
conflict/disgruntlement from the patient. Eventually, it becomes easier for a given
medication to be added to the patient’s repeat list than it is to deal with the repeat
(refill) request monthly. Once the medication is on the patient’s repeat list, they are
able to go to any pharmacy and obtain the medication as long as their number of
repeats does not run out. This seems very similar to the practice in the United States;
however, providers in Scotland will often add “999” when they are prompted for the
number of repeats as the medication is being added to the repeat list. Thus, the patient
may receive a medication, for years that was meant to be used only once for an acute
event, from their pharmacy upon request without this medication being reviewed by
any professional regularly. Pharmacists have the ability to play an important role in
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combating the repeat issue. The pharmacist from Practice 4 always attempted to
“clean up” the repeat list, while this was done less than 50% of the time by others.
These findings illustrate a need for a standardized procedure and teaching guideline.
The last notable observation was that pharmacists perform MR were calling
their patients regarding the changes made to their medications a small percentage of
the time. This finding led to the crucial action of contacting the patient with all
changes being a required step in the Medication Reconciliation Flow Sheet. Most of
the hesitation surrounding this contact came from pharmacists not wanting to be
redundant. However, contacting their patients with medication changes should be
seen as the duty of any pharmacist, regardless of who contacted them previously.
This could build the pharmacist-patient relationship; as well as, plant pharmacists as
part of the foundation for improved primary care services.
These observations led to the development of the Medication Reconciliation
Flow Sheet as a standardized guide to follow. This resulting flow chart can be found
in appendix 5. This was invented using the data found in this section to identify ways
in which pharmacists diverge in conducting MRs in hopes of streamlining the process
for everyone. This flow chart will serve as a guide for all future pharmacists doing
primary care medication reconciliations in this region going forward.
The original study protocol stated a workup including the situation,
background, assessment, and recommendation would be completed on the most
severe errors recorded. However, upon practice it was clear this was impossible due
to the nature of our observations. The tendency when a severe issue arose was the
initiation of follow up with the GP, clinic, hospital, or patient. This follow up was not
instant and thus the resulting actions taken to resolve the errors were never observed.
This is why the errors in appendix 6 simply state the issue and what steps the
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pharmacist then took to resolve the error. It was possible to categorize the severity of
these errors, which can also be found in appendix 6.
Another point of variation was how pharmacists resolved errors found during
the MR process. Depending on the practice, some pharmacists were more likely to use
their clinical judgment to resolve an issue, while others almost always deferred to
GP’s judgment. This could be explained by each individual’s comfort level at their
practice. Their comfort level could be reflected by length of employment at a
particular practice and resultant familiarity with documentation systems. This
information could also reflect a difference in pharmacist’s knowledge or practice
experience. This difference could not be resolved by our tool; however, further
training focused on primary care pharmacy practice could be beneficial in future
developments.
Finally, pharmacists led medication reconciliation is a public health issue
because of the potential to improve health outcomes while reducing medication
related errors. Pharmacists’ involvement in this area of healthcare could reduce the
number of overall prescriptions per person, reduce healthcare dollars spent on
medications, prevent drug-drug and drug-disease interactions, and promote overall
effective and safe medication use by patients in the community. Interestingly, this
study may have difficulty impacting the current system in the United States. One
barrier is the small number of pharmacists in primary care centers. (13) Community
pharmacies may not be the ideal setting for medication reconciliation services due to
workflow issues. (14) Two examples of these workflow issues could include barriers in
communication between the pharmacist and a patient’s primary care provider or
simply pharmacies being too busy to take on additional responsibilities. Additional
barriers to this practice coming to the United States include lack of awareness of the
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roles pharmacists can play in primary care settings as well as laws and regulations
surrounding pharmacists’ payment in this setting. (15) Thus, an interesting public health
study would examine the potential pharmacists’ hold for transitions of care in the
primary care setting of the United States. Specifically, addressing the ways
pharmacists take part in the primary care setting given the barriers present in the
United States and how their role could be influenced if barriers were to change.
Conclusion
Pharmacists are uniquely positioned to have a lasting impact on primary care.
The successful implementation of pharmacist driven medication reconciliation is a
building block towards fewer medication errors, improved patient-pharmacist
linkages, and improved pharmacist-physician relationships. The foundation of the
MR process should be the guidelines presented in the Medication Reconciliation Flow
Sheet for completing this processes in the primary care setting. Standardization of
these guidelines will ensure current and future primary care pharmacists are being
used efficiently and at the peak of their abilities. Future studies should examine
differences seen in pharmacists’ procedures after the implementation of these
guidelines. Repeating this study at the same practices in a year after the
implementation of the Pharmacist Medication Reconciliation Flow Sheet would be a
worthwhile endeavor. Additionally, future directions should include GPs in the
planning and execution of studies in an attempt to unify the medication reconciliation
process in primary care across professions.
There are many aspects of this project that have increasing relevance to public
health. As the discussion above indicates, pharmacist’s involvement in primary care
offices of the Scottish health board studied has the potential to reduce errors at
transitions of care and improve the overall level of care the patient receives. However,
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these changes cannot be successful without proper implementation. Therefore, the
guideline and flow sheet described in this study support a public health initiative to
improve primary care practices by providing necessary assistance for pharmacist
entering this area of practice.
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Appendix 1 - Agreement Form for pharmacists
participating in the project
Evaluation of the Medicine Reconciliation Process in Primary
Care

-------------------------------------- (Print Name) agree to the pharmacy
student observing my work while undertaking medicine
reconciliation within __________________ (GP Practice) as part of
data collection of the above named evaluation project.
I have read and understood the protocol.
Signature___________________
Date________________________
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Appendix 2 - Original NHS Medication
Reconciliation Template Guideline
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Appendix 3Observation Tool
Med Rec Tool
1. Clinic Name
Mark only one oval.
Eskbridge
Riverside
Trenent
Bonnyrig
Murryfield 1
2. Who implemented the workflow?
Mark only one oval.
Doctor
Pharmacist
Admin Staff
3. Start Time
Example: 8:30 AM
4. Clinic letter or Discharge?
Mark only one oval.
Clinic
Discharge
Duplicate
5. Appointment/Discharge Date
Example: December 15, 2012
6. Date Written
Example: December 15, 2012
7. Date Received
Example: December 15, 2012
8. Date Processed
Example: December 15, 2012
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Appendix 4- Results from Observations
Practice Name

Practice 1

Practice 2

Practice 3

Practice 4

Pharmacists Avg.

Average days between visit and
letter/IDL written

5.6

0.8 (outlier of
48)

10.9

3.6

5.2

Average days between letter/IDL
written and received by the surgery

3.0

2.4

2.5

2.6

2.6

Average days between letter/IDL
received and processed

2.3

0.5

1.0

1.4

1.3

14.8**

7.9

7.8

6.9

7.5

Average time to complete the MR
process - Clinic letter (minutes)

14.8

8.9

7.9

6.7

9.6

Average time to complete the MR
process - IDL (minutes)

N/A

6.2

7.4

7.5

7.0

Proportion of MR with errors found
in the letter/IDL during the Process

44.44%

21.43%

14.29%

15.00%

23.79%

Percentage of MR with more than
10 medications on the patients
repeat list (duplicates removed)

44.44%

42.86%

28.57%

22.50%

34.59%

Percentage of MR in which changes
were made to the Pt's medication
list (if no changes MR excluded)

66.67%

77.78%

84.21%

100.00%

82.16%

Were the repeats analysed during
the MR?

88.89%

46.15%

90.48%

100.00%

81.38%

Was the patient or caregiver
contacted with changes?

55.56%

33.33%

13.33%

30.77%

33.25%

12.50%

0.00%

50.00%

100.00%

40.63%

88.89%

92.86%

90.00%

97.50%

92.31%

MR forwarded to GP with questions
about prescriptions?

44.44%

14.29%

9.52%

5.00%

18.31%

Clinical decision made by
pharmacist if there was an error

16.67%

33.33%

33.33%

71.43%

38.69%

Was the MR completed within 48hrs
of receiving the letter or IDL?

88.89%

100.00%

95.24%

80.00%

91.03%

Percentage of letters/IDLs in
workflow found to be duplicates

10.00%

17.65%

8.70%

6.98%

10.83%

Average time to complete a MR for
the practice (minutes)

Were allergies checked during the
MR?
Was the MR read-coding
completed?
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Appendix 6 – Errors found during observation of MRs
Pt/Type
1
(Clinic
Letter)

Problem
Unclear directions about how to increase
the patient’s anti-epileptic medications
to the desired dose

Solution
Pharmacist sent to
GP for follow up

NCC MERP
Category E

EQUIP
Serious

2
(Clinic
Letter)

Discrepancy between the clinic letter and
patient’s medication list. Clinic Letter
says 300 mg Venlafaxine versus 337.5
mg on the surgeries medication list.

Category D

Minor

3
(IDL)
4
(IDL)
4*
(IDL)

Only first page of clinic letter received
(1/2).
1. Lisinopril was omitted from the
discharge letter.
2. Isosorbide Mononitrate has not been
reordered by patient since May, may be
causing headache, and it is still on
repeat.

Pharmacist
changed to acute
so a GP would
have to see it if
she requested
again.
Pharmacist went
forward with MR.
Sent on to GP to
look at.
Sent on to GP to
look at.

Category A

N/A

Category D

Serious

Category E

Serious

5
(Clinic
Letter)

Discharge letter includes cetirizine;
cetirizine not on repeat, only received
once in march.

Category C

Minor

6
(Clinic
Letter)

Unclear to pharmacist how the patient
has been reducing their dose of steroid
by 1 mg while the patient only gets 5mg
tablets.
Zolpidem dose was wrong in the letter in
comparison to the current repeat. It is
expected that the letter reflects the actual
amount he is taking (half of a 7.5) while
the chart itself only says 7.5mg.

Email sent on to
the physician
regarding other
potential conflicts
found in the letter.
Pharmacist
attempted to call
patient.

Category E

Significant

Pharmacist decide
they had missed
the (1/2) tablet
instructions.

Category C

Significant

7
(Clinic
Letter)

8
(Clinic
Letter)

Miscommunication about directions on
the eye drop, two drops to right eye
versus 1 drop to both eyes.

Pharmacist
initiated follow up
with physician

Category D

Serious

9
(Clinic
Letter)
10
(Clinic
Letter)

No dose listed on the letter (Paglaflozin).

Pharmacist chose
25 mg once daily

Category D

Serious

No dose or duration
(Dexamethasone/neomycin)

Pharmacist
initiated follow up

Category D

Significant

11
(IDL)

Patient usually on Pizotifen 500
micrograms, listed as 20MG in letter.

Pharmacist left at
500 mcg.

Category G

Potentially
Lethal
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